{"links":{"feed":"https://www.erudio.com/reports/harmoni-7-nct06767514/feed.json","html":"https://www.erudio.com/reports/harmoni-7-nct06767514","json":"https://www.erudio.com/reports/harmoni-7-nct06767514.json","markdown":"https://www.erudio.com/reports/harmoni-7-nct06767514.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"harmoni-7-nct06767514"}},"request":"https://www.erudio.com/contact?report=harmoni-7-nct06767514"},"offer":{"cited_clinicians":11,"cited_commentary_sources":43,"verified_hcp_statements":109,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":15},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"harmoni-7-nct06767514"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=harmoni-7-nct06767514","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/harmoni-7-nct06767514","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 109 verified statements · 41 from 11 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T10:06:46.535425Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":16,"no_commentary_found":2},"aspects":[{"claim_count":13,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":7,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":6,"title":"Primary endpoint: Progression free survival (PFS)"},{"claim_count":1,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":1,"title":"Secondary endpoint: Objective response rate (ORR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: Disease control rate ( DCR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":0,"title":"Secondary endpoint: Duration of response (DoR)"},{"claim_count":9,"coverage":"discussed","id":"T6","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":4,"title":"Secondary endpoint: Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":15,"coverage":"discussed","id":"T8","registry_field":"armsInterventionsModule.armGroups","source_count":10,"title":"The comparison"},{"claim_count":11,"coverage":"discussed","id":"T9","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T10","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":13,"coverage":"discussed","id":"A1","source_count":4,"title":"Therapeutic rationale and possible replacement of checkpoint-inhibitor backbones"},{"claim_count":16,"coverage":"discussed","id":"A2","source_count":13,"title":"Geographic translation, evidence quality and regulatory expectations"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":2,"title":"Censoring, follow-up and discretionary discontinuation questions"},{"claim_count":6,"coverage":"discussed","id":"A4","source_count":3,"title":"ADC alternatives and the case against automatic intensification"},{"claim_count":3,"coverage":"discussed","id":"A5","source_count":1,"title":"First-line treatment, later cell-therapy fitness and tissue planning"},{"claim_count":2,"coverage":"discussed","id":"A6","source_count":1,"title":"Conditional TIL combination development and a possible selective niche"},{"claim_count":1,"coverage":"discussed","id":"A7","source_count":1,"title":"China-specific readiness to use the approach"},{"claim_count":10,"coverage":"discussed","id":"A8","source_count":5,"title":"Investment thresholds and cross-application development interpretations"}],"counts":{"beyond_population_findings":6,"beyond_population_statements":30,"cited_clinicians":11,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":9,"physician, Pathology":1},"cited_physicians":11,"cited_sources":43,"claims_by_expression_type":{"comparison":7,"interpretation":37,"opinion":23,"question":7,"restatement":11,"uncertainty":6,"unspecified":18},"claims_by_kind":{"interpretation":1,"source_observation":108},"clinician_statements":41,"evidence_units":78,"findings":13,"organisational_accounts":11,"people_cited":26,"people_identity_verified":15,"people_total":27,"screened_sources":67,"verified_claims":109},"findings_index":[{"cited_clinicians":5,"id":"F1","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":7,"views":11},"limitations":3,"links":{"context":0,"support":23},"ma_question":true,"named_voices":6,"passages":13,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"HARMONi-2 PD-L1-high OS: what speakers say","evidence_line":"22 statements from 6 speakers in 7 sources, 1 of them a podcast or video"},{"cited_clinicians":4,"id":"F3","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":1,"views":5},"limitations":4,"links":{"context":0,"support":10},"ma_question":true,"named_voices":7,"passages":9,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"PD-L1: what speakers say","evidence_line":"9 statements from 7 speakers in 7 sources, 1 of them a podcast or video"},{"cited_clinicians":1,"id":"F4","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":1},"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":2,"passages":4,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Censoring: speakers question it; one queries non-toxicity-coded stops","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-acc64645d1e91a36964f"],"clause":"one queries non-toxicity-coded stops","holders":1},"cited_claim_ids":["claim-ba55309c1cf2ce9a7345","claim-d63868e69ede1110bcb1"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"4 statements from 2 speakers in 2 sources","holder_line":"2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “one queries non-toxicity-coded stops”"},{"cited_clinicians":0,"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":0,"views":2},"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"TROP2 ADC combinations: where speakers split on cross-trial trade-offs","title_holders":{"cited_claim_ids":["claim-5764e5c29b2d60c7d4b4","claim-670f221019744123aade","claim-29f3555985c8468f6e54","claim-8d22006079e0a7db9bf3"],"clinicians":false,"holders":2,"sides":[{"cited_claim_ids":["claim-5764e5c29b2d60c7d4b4"],"holders":1},{"cited_claim_ids":["claim-670f221019744123aade","claim-29f3555985c8468f6e54"],"holders":1},{"cited_claim_ids":["claim-8d22006079e0a7db9bf3"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"5 statements from 2 speakers in 2 sources","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other"},{"cited_clinicians":0,"id":"F6","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":3},"limitations":3,"links":{"context":1,"support":3},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"First-line VEGF: why a speaker worries it could limit TIL eligibility","title_holders":{"cited_claim_ids":["claim-cf756379ede5f07dbf5d"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"3 statements from 2 speakers in 1 source","holder_line":"1 of the 2 named speakers in this finding holds this view"},{"cited_clinicians":6,"id":"F7","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":11},"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":10,"passages":13,"sources":12,"sources_by_kind":{"commentary":10,"media":2}},"title":"Global validation: some speakers await it; some weigh regional enrollment","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-66781cda178bf2ff68ce","claim-66a5d159b63a0b1883b6","claim-cd49830f7cfc9395ebe6"],"clause":"some weigh regional enrollment","holders":2},"cited_claim_ids":["claim-41fdb17a5f85d52d4c54","claim-f5123fc23e8a793962ad","claim-6c5ccd201a378f576a12","claim-6c28ce697d049fd5d693","claim-90e84e92876c12381b97","claim-13f870e9383f0ca0ff53","claim-01628c544313f7e7006a"],"clinicians":false,"holders":5,"speakers":10,"view":"reading"},"evidence_line":"15 statements from 10 speakers in 12 sources, 2 of them podcasts or videos","holder_line":"5 of the 10 named speakers in this finding hold this view; 2 of the 10 hold its caveat, “some weigh regional enrollment”"},{"cited_clinicians":0,"id":"F8","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":2,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Ivonescimab in China: why a speaker sees a tentative case for use now","title_holders":{"cited_claim_ids":["claim-ee08a0bf06c27ed120df"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":2,"id":"F2","population":"beyond","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":1,"views":7},"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":4,"passages":6,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"VEGF toxicity: where speakers split on manageability and added risk","title_holders":{"cited_claim_ids":["claim-d746308dbcfb174f20d6","claim-575834c754a836c686b3","claim-2b96b4f224dc987d5894","claim-c8815a8552c0542d8b51","claim-90e84e92876c12381b97"],"clinicians":false,"holders":4,"sides":[{"cited_claim_ids":["claim-d746308dbcfb174f20d6","claim-575834c754a836c686b3","claim-2b96b4f224dc987d5894"],"holders":2},{"cited_claim_ids":["claim-d746308dbcfb174f20d6","claim-c8815a8552c0542d8b51","claim-90e84e92876c12381b97"],"holders":3}],"speakers":4,"view":"split"},"evidence_line":"10 statements from 4 speakers in 4 sources, 1 of them a podcast or video","holder_line":"4 of the 4 named speakers in this finding take a side on this question: 2 on one side, 3 on the other, 1 on both"},{"cited_clinicians":0,"id":"F9","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"limitations":3,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"TIL–ivonescimab: a speaker would explore it if PD-1/VEGF became standard","title_holders":{"cited_claim_ids":["claim-58af56693c56814aa834"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":1,"id":"F10","population":"beyond","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":4,"views":5},"limitations":5,"links":{"context":1,"support":13},"ma_question":true,"named_voices":2,"passages":8,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"HARMONi-6: a speaker expects significant OS benefit from PFS gains, awaiting OS data","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-72c47791bf65162a70d7"],"clause":"awaiting OS data","holders":1},"cited_claim_ids":["claim-72c47791bf65162a70d7"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"12 statements from 2 speakers in 4 sources, 2 of them podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view; 1 of them holds its caveat, “awaiting OS data”"},{"cited_clinicians":0,"id":"F11","population":"beyond","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":7},"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":2,"passages":7,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Investing: speakers await OS or global data; one differs on FDA impact","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-6f9a3edc7bfd70032256","claim-12adf03dde891a267f09"],"clause":"one differs on FDA impact","holders":1},"cited_claim_ids":["claim-962d7b298b648cfca625","claim-5cb6dd379a7303495a08","claim-249ba5c6286fabea81e2","claim-c86071cb25c08f317074"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"10 statements from 2 speakers in 5 sources","holder_line":"2 of the 2 named speakers in this finding hold this view; 1 of the 2 holds its caveat, “one differs on FDA impact”"},{"cited_clinicians":1,"id":"F_context_C95","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":0},"limitations":2,"links":{"context":0,"support":1},"ma_question":false,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Ivonescimab overview: a clinician welcomes it and awaits HARMONi-6 OS","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-4bda27d1478fa5ae0d72"],"clause":"await HARMONi-6 OS","holders":1},"cited_claim_ids":["claim-4bda27d1478fa5ae0d72"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “await HARMONi-6 OS”"},{"cited_clinicians":1,"id":"F_H6_expectations","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":0},"limitations":4,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"HARMONi-6: a speaker expects significant OS gain and floats a safety learning curve","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-4c284feec33e5a2bb9ac","claim-f7ae8bbeffff6b263d5b"],"clause":"float a safety learning curve","holders":1},"cited_claim_ids":["claim-72c47791bf65162a70d7"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"4 statements from 2 speakers in 2 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view; 1 of them holds its caveat, “float a safety learning curve”"}],"open_question":{"basis":"From finding F1 (22 statements from 6 speakers in 7 sources)","cited_claim_ids":["claim-a6613e7e59b55d97ac22","claim-7487d7961c64958395b9","claim-5e1bf56b437044a48f97","claim-abdb9e76cd1a7e0bf374","claim-861c9299903fbcafff64","claim-ff1abf349396b7c2b4c0","claim-cdbcbf5c35e6e7487a1c","claim-d63868e69ede1110bcb1","claim-fb46b0ddc3013551b3c9","claim-8be281f6355cfa229e0a","claim-7b0744aad8c7c1381ff0","claim-90e84e92876c12381b97"],"finding_ids":["F1"],"question":"What do clinicians need HARMONi-7 to show about overall survival and VEGF-related toxicity before replacing pembrolizumab with ivonescimab as first-line monotherapy for PD-L1-high metastatic NSCLC globally?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Clinicians welcome the high-PD-L1 signal without treating global replacement as settled"},{"id":"section-2","level":2,"title":"Clinicians distinguish the high-PD-L1 monotherapy choice from lower-PD-L1 comparator objections"},{"id":"section-3","level":2,"title":"One X account leaves censoring, follow-up and discretionary discontinuation questions unresolved"},{"id":"section-4","level":2,"title":"Two X accounts weigh alternative ADC regimens differently, and one argues against automatic intensification"},{"id":"section-5","level":2,"title":"One X account raises a downstream eligibility concern rather than reporting sequencing harm"},{"id":"section-6","level":2,"title":"Clinicians seek international confirmation, while X replies emphasize regional representation"},{"id":"section-7","level":2,"title":"One X account's tentative readiness to act is explicitly China-specific"},{"id":"section-8","level":2,"title":"Beyond the trial population"},{"id":"section-9","level":3,"title":"One clinician's reassuring safety reading depends on selection, while other accounts retain added-risk concerns"},{"id":"section-10","level":3,"title":"One X account proposes conditional TIL combination development, not routine treatment addition"},{"id":"section-11","level":3,"title":"A relayed interview expects broader first-line change but reserves stronger evidence conclusions"},{"id":"section-12","level":3,"title":"One interview speaker expects HARMONi-6 OS benefit and tentatively suggests a safety learning curve"},{"id":"section-13","level":3,"title":"Public accounts make conflicting regulatory extrapolations and explicitly investment-oriented judgments"},{"id":"section-14","level":3,"title":"One clinician welcomed an ivonescimab overview and eagerly awaited HARMONi-6 OS results"},{"id":"section-15","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":11},{"id":"F3","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T2","label":"Primary endpoint: Progression free survival (PFS)"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T3","label":"Secondary endpoint: Objective response rate (ORR)"},{"findings":[],"id":"T4","label":"Secondary endpoint: Disease control rate ( DCR)"},{"findings":[],"id":"T5","label":"Secondary endpoint: Duration of response (DoR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T6","label":"Secondary endpoint: Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":4},{"id":"F7","shared_claims":2}],"id":"T7","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":8},{"id":"F5","shared_claims":5},{"id":"F8","shared_claims":1}],"id":"T8","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T9","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F7","shared_claims":3}],"id":"T10","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T10:06:46.535425Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T10:33:42Z","record_hash":"9c139089a94ab3d6696852b83a3222adb38982b30c17c62079409b674c18e40e","release_hash":"9bc7431a57813b033e040c199a754f97e897c8191e14b51ab21c7d57b9af7291","report_id":"erudio-nct06767514","run_id":"065cd7fe-7688-49fb-838c-6084309bd406","schema_version":"5.0","slug":"harmoni-7-nct06767514","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For HARMONi-7, the clinicians cited find support in HARMONi-2’s PD-L1-high survival findings, but stop short of endorsing worldwide treatment change. One medical oncologist considers added VEGF toxicity manageable with patient selection; another cites it among reasons for caution. Discussion of the trial itself is limited; earlier ivonescimab evidence supplies context rather than its outcomes. The cautious readings call for fuller disclosure and confirmation beyond China.","examples":[],"meta_description":"67 sources screened · 109 verified statements (41 from clinicians verified by NPI or staff page) from 43 sources · 13 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T10:33:42Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":67},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a question about ivonescimab’s potential clinical role in lung cancer and the need for further trial data.","2 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","36 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 43 sources about other trials or topics are not included.","The sources reviewed for this edition do not include a HARMONi-7 protocol or results publication. Statements about enrollment rationale, statistical power and future outcomes are not resolved against those primary documents here.","No exact product-label source was available for either named injection. Regulatory predictions and safety interpretations are reported as their authors' views, not as an assessment of authorized use.","The sources chiefly concern explicit HARMONi-7 references. Discussion of the same treatment decision without the trial name, with alternative spellings or in earlier material may be missing.","Two short passages in one social thread were not fully assessed, and another relevant reply is not represented in the report's statements. Additional questions or qualifications may therefore be missed.","Comments concern different evidence-disclosure stages. Publication dates alone do not establish presentation or interview dates, subsequent knowledge or changes of mind.","Public accounts, reported polls and reposts do not provide an independent-HCP denominator, and some public authors' clinical roles are not established. The report cannot establish prevalence, consensus or actual prescribing patterns.","Several efficacy, safety and regulatory statements concern HARMONi-2, HARMONi-6 or another explicitly distinguished study rather than HARMONi-7. Combination-therapy expectations and tentative comparisons with earlier reports should not be treated as demonstrated monotherapy benefits or safety advantages."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":40,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":43},"count":43,"evidence_window":{"end":"2026-11-18","start":"2024-09-08"},"retrieval_snapshot":"2026-11-19T08:17:11.079708Z","timeline":[{"count":2,"week":"2024-W36"},{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W12"},{"count":5,"week":"2025-W17"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W32"},{"count":3,"week":"2026-W36"},{"count":9,"week":"2026-W37"},{"count":4,"week":"2026-W38"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"},{"count":4,"week":"2026-W47"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06767514:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06767514:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4drh6srkc5sqwbdjhvk6oi7j-3lno3fvxhh227","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-5zww7zorx2ajw7hqrhuix3ba-3mqavvw7ohq27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3lwy7wtdqnz2r","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-onq7arnmwqwb5wctfkgwkyl4-3mpyxnr76sc2x","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e4dc3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832807899032162526:a7a3bffc-3cab-4f65-aa1d-446dd9940214","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832808888766529764:16f68f02-a5be-409f-9c18-061fbacf252e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832820106503798833:5d8670be-0034-4b33-86b8-8eaf40466373","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833071454037975451:88ded9fc-d05d-4eef-94af-56a448bb391e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833203905137656014:a3215fc2-66df-4405-b010-5932c93f4ed5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1842198326990573658:fdcf2de1-0ffa-49b1-abc4-8810d8617341","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1851611323248857475:0d78a6c7-5a9c-44fb-8bdd-85ca0511237d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1857051189117882532:d00ded33-b55a-400a-9c6e-182f3083ce10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879168998253740224:f6ddb1c4-d537-4a5e-8200-5407bf3dd9eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1886782537608859792:254b96ae-5371-4e5d-8667-16b657c62c13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1893996271179845953:1d250ecb-7f7e-4e10-8e78-7664d783775f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1903439733696389138:f889559b-581a-4653-ae0b-6c2003991a78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915844742627074549:5595206c-0ba2-4b6a-8eb1-0c892599b8a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915868402658512961:52f6faa4-946e-42a3-aef1-9e3157988265","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915912233365672440:83cfc32f-e4a1-4224-aff5-15eddc54ba2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916339198489203078:4d4788b2-3a4c-47db-ad90-3243c61492ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916753584160465131:b13df8c4-368e-404b-b46a-11845d532f7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918035270642880867:c58d2921-91a8-4a17-8516-c8b9d1890ba2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925978191622987925:793c5892-8ed9-4e42-a786-81ab1abc4ad3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1959138283100815517:93d693e8-c4f1-419a-9921-f44f1ea0b2c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960742096945734139:d69dfec1-0623-4cd3-9087-3609a675fa1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964778181564719534:0af485ad-19d6-4688-b9f0-c27bd66a5cc2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980230982562455953:da67ddff-5d9d-4df7-8785-c18215c47e92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037850267018822098:9af37613-f154-4c9c-8ebe-0f7a5cb77187","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053414428658307180:b618359f-e9a7-4c4c-b067-7b316fd85ab1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058501723421843828:96d7f358-cf5e-4742-8065-f0102bea1035","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061270271554891848:d25c3efc-b729-4253-9cf3-64cb59d61750","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075380733347082739:30a3d300-2add-4d8e-b6f6-7a672880be19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085593966032863423:02541a0d-5c32-419e-a4b9-434fdc420da4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095378774410019308:e0495757-36d6-480d-accd-fe2cb301f365","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095450449176588367:71109682-f6f6-4922-aa1c-487178ec4add","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095461509048492214:59af829c-55a9-4b69-a0e9-a7663cc82ca8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095466311023558956:cc26b47c-8c5c-4271-8bfa-dab64067e604","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097032484806398149:4d2bafde-b93f-4524-8f26-45590553a287","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098945141193232389:9a7c1cbc-feaf-4ec4-bcda-001cfa201061","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098978479224013299:3734d65b-4fdd-4490-a326-407ff5fcbcf1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099051847054967234:3ba5a85c-32d2-4b2f-9a7e-a5211ecfd167","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099077776208797743:4318cc14-73bc-494c-acc7-3317d0786149","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099091085607735512:570f4b9e-509f-4d16-8df8-454c5f345af3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099109032376279135:90818482-1da4-4f08-8f73-357754ff2d5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099122205858611543:709eae6a-8475-4f81-ae97-1eb6ab2f831e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099180197601780063:c1801529-f4b7-444d-86fa-40a9f4bb6884","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099205343142179140:c89e2982-a548-4465-b5b7-d928448bcc32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099380470962147379:73015108-1283-4cec-b3c1-02ea7a38c95a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099717902035562937:f5066c5e-1250-43fc-94f3-013fe04810f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099720619738722453:705f345c-8a4f-4e21-a352-f6c33580e582","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099755964794872182:cf52522c-1d5f-4768-86e8-70cb57aa0589","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100138205458612657:8e2e7ecc-e5ab-4970-8d7c-4cc7eddfb94c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102069095558721677:6a599e10-48a5-441f-9755-1e572898480d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102431113561919872:7e947881-cc5b-4b98-bfe8-98a664e8433a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102803866525802843:ac786900-f897-47ce-a23e-cdfdb36a7549","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106382651418615942:0710b7ec-cfb0-492d-9911-4227d1b2a13c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108971304321785975:ff39df17-1ebf-4a42-ba4f-1a8cd8f8b59e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113684285014307078:68d6daf3-219c-411e-a668-9a5b02f97678","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114401724714934556:528f7df1-86e5-43d8-bdbb-189a9b61608f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114402745406939519:033c5d21-dd59-4ad5-a51f-bd4ef94b9cf9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115398173971579010:47b77e14-b76d-4eeb-b3d5-4bcff717795b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122610581593309512:4b62361b-35ab-450f-9407-1fbf91ca27c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122742240653038069:61327357-5755-41cb-91a3-409907856b51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122767586144518497:7abc4543-c4af-4373-a8b1-cf9bd4fcffa8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122901406399021456:eda23d10-b5d6-44ef-993c-ccb4ba2aea4b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9qeSxkaVW3g","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":61,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":67},"count":67,"evidence_window":{"end":"2026-11-18","start":"2024-09-08"},"retrieval_snapshot":"2026-11-19T08:17:11.079708Z","timeline":[{"count":3,"week":"2024-W36"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W12"},{"count":5,"week":"2025-W17"},{"count":2,"week":"2025-W18"},{"count":1,"week":"2025-W21"},{"count":2,"week":"2025-W34"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W23"},{"count":3,"week":"2026-W28"},{"count":1,"week":"2026-W32"},{"count":4,"week":"2026-W36"},{"count":10,"week":"2026-W37"},{"count":6,"week":"2026-W38"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":3,"week":"2026-W43"},{"count":1,"week":"2026-W44"},{"count":4,"week":"2026-W47"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":23,"publication":0,"registry":0,"regulatory":0,"x_thread":80,"x_video":0,"youtube":5}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"ivonescimab","slug":"ivonescimab"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"HARMONi-7","aliases":["HARMONi-7","Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression"],"brief_title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer"],"display_condition":"first-line metastatic NSCLC with high PD-L1 expression","display_interventions":[["ivonescimab"]],"enrollment":{"count":780,"type":"ESTIMATED"},"interventions":[{"name":"Ivonescimab Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Pembrolizumab Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"}],"nct_id":"NCT06767514","official_title":"A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-04","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 36 months"},{"measure":"Progression free survival (PFS)","timeFrame":"Up to approximately 36 months"}],"registered_date":{"date":"2025-01-10","type":"ACTUAL"},"registry_last_updated":"2026-11-18","registry_url":"https://clinicaltrials.gov/study/NCT06767514","short_name":"HARMONi-7","short_name_basis":"registry_acronym","sponsor":"Summit Therapeutics","start_date":{"date":"2025-02-27","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"SMT112-3007","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}